Your browser doesn't support javascript.
loading
Virtual reality for COPD exacerbation: A randomized controlled trial.
Kizmaz, Erhan; Telli Atalay, Orçin; Çetin, Nazli; Ugurlu, Erhan.
Afiliação
  • Kizmaz E; Munzur University, Health Science Faculty, Tunceli, Turkiye. Electronic address: erhankizmaz@hotmail.com.
  • Telli Atalay O; Pamukkale University, Physiotherapy and Rehabilitation Faculty, Denizli, Turkiye.
  • Çetin N; Pamukkale University, Pulmonology Department, Denizli, Turkiye.
  • Ugurlu E; Pamukkale University, Pulmonology Department, Denizli, Turkiye.
Respir Med ; 230: 107696, 2024.
Article em En | MEDLINE | ID: mdl-38857811
ABSTRACT

BACKGROUND:

Pulmonary rehabilitation (PR) is an effective treatment method for chronic obstructive pulmonary disease (COPD). However, individuals with chronic diseases that require lifelong treatment and experience exacerbations need motivational methods.

OBJECTIVES:

The aim of this study was to examine the effects of virtual reality on symptoms, daily living activity, functional capacity, anxiety and depression levels in COPD exacerbation.

METHODS:

Fifty patients hospitalized for COPD exacerbation were included in the study. They were randomly assigned to two groups. Twenty-five patients participated in a traditional PR (once-daily until discharge), including pedaling exercises. The second/25 patients followed the same protocol but experienced cycling simulation in the forest via virtual reality (VR + PR). All patients were evaluated using 1-minute/Sit-to-Stand test (STST), modified-Medical Research Council (mMRC) scale, COPD Assessment test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activities of Daily Living (LCADL) before and after the treatment.

RESULTS:

The STST showed an increase in both groups post-treatment, notably higher in the VR + PR (p = 0.037). Dyspnea levels and CAT scores decreased in all patients, but the decrease was greater in the PR + VR group for both parameters (p = 0.062, p = 0.003; respectively). Both groups experienced a reduction in the HADS scores compared to the pre-treatment, with a more significant decrease in depression and the total score in the VR + PR (p < 0.05). LCADL's sub-parameters and total score, excluding household, decreased in both groups after treatment (p < 0.05). The improvement was more substantial in the VR + PR.

CONCLUSIONS:

Virtual reality provides benefits in the management of COPD exacerbations and can be used safely. CLINICAL TRIAL REGISTIRATION Registered at clinicaltrials.gov, registration ID NCT05687396, URL www. CLINICALTRIALS gov.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ansiedade / Atividades Cotidianas / Doença Pulmonar Obstrutiva Crônica / Realidade Virtual Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ansiedade / Atividades Cotidianas / Doença Pulmonar Obstrutiva Crônica / Realidade Virtual Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article